Abstract Library

#4355 Emergence of DNA damage repair clonal haematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumours

Introduction: In neuroendocrine tumours (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity. Clonal haematopoiesis (CHIP) is considered a risk factor for therapy-related myeloid neoplasms (t-MN).

Conference:

Presenting Author: Hadoux J

Authors: Loyaux R, Hadoux J, Oziel-Taieb S, Durand A, Bouhier Leporrier K,

Keywords: PRRT, clonal haematopoiesis, DNA Damage Repair, therapy-related myeloid neoplasm, Neuroendocrine tumour,

#3827 Prevalence of Clonal Hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to Lutetium 177 dotatate therapy (Lu177) and the risk of cytopenia – A prospective study of 37 patients

Introduction: Lu177 has shown efficacy in advanced NET but with significant hematologic toxicity, including therapy-related myeloid neoplasm (t-MN). CH is defined by acquisition of somatic mutations in hematopoietic stem cells with potential for expansion over time.

Conference:

Presenting Author: Sonbol M

Authors: Sonbol M, Kusne Y, Lasho T, Elsabbagh Z, Mangaonkar A,

Keywords: clonal hematopoiesis, neuroendocrine, PRRT, Lu177, t-MN, CHIP,

#3176 Tissue sample collection from patients with neuroendocrine tumor (NET) treated with peptide receptor radionuclide therapy (PRRT) for future blood disease research

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with metastatic NET. However, the development of therapy-related myeloid neoplasms (t-MN) is an infrequent but serious complication. T-MN after PRRT occurs at higher frequency compared to other solid tumor chemotherapies and harbour unfavourable genetic mutations with poor treatment outcomes. Prospective data is needed to explore pre-existing genetic factors and predictive biomarkers to minimise t-MN risk.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Michael M, Alipour R, Akhurst T, Hicks R,

Keywords: t-MN, PRRT, PRCRT, marrow biopsy,

#2734 Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review

Introduction: Therapy-related myeloid neoplasm (t-MN) has been reported as a potential long-term and frequently lethal adverse event after PRRT in NET. However, the incidence, time of diagnosis, and nature of t-MN is unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sonbol M

Authors: Sonbol M, Hilal T, Halfdanarson T,

Keywords: PRRT, t-MN, therapy-related myeloid neoplasm, leukemia, NET, MDS,